- Poll of the Day
Stocks to Buy
Finding the right stock to buy is one of the most difficult parts of investing.
At Investorplace, our experts help expedite that process by providing reliable information that will assist you in choosing what stocks to invest in. Whether the ultimate goal is to find steady income or earn a quick buck, our staff provides advice to help you find a strong dividend stock, a penny stock with potential, or, plain and simple, a good stock to buy.
Check out the stocks our experts pick as best buys right now.
A disappointing Alcoa earnings report and outlook sent AA stock more than 3% lower on Thursday. Here's why that may have been a mistake. Read Article
JPMorgan Chase & Co. and Wells Fargo & Co are set to report very different bottom-line results when they deliver quarterly earnings. Read Article
Habit Restaurants and Shake Shack both launched IPOs recently and investors were more than enthusiastic. But looking at the numbers of HABT and SHAK, and one of these burger stocks is clearly superior. Read Article
Walgreens (WBA) stock is up big on earnings today. But ambitious expansion, wise execution, and an eye for innovation are Walgreens' biggest assets. Read Article
An Iran nuclear deal could push more crude oil to market and hurt margins at refineries, but Valero Energy Corporation (NYSE:VLO) can weather the storm. Read Article
This week, these five stocks have the best ratings in Earnings Surprises, one of the eight Fundamental Categories on Portfolio Grader. Read Article
Rite Aid Corporation is gaining operational momentum at the same time it made a smart acquisition, and that spells upside for RAD stock. Read Article
Lions Gate (LGF) stock sold off hard on Wednesday after a 10 million-share secondary stock offering. Here's why you should ignore it entirely. Read Article
A conference of high-powered business executives next month will give some insight about hot sectors for investors in the next three years. These three stocks are focused on three important segments -- women, seniors and Millennials. Read Article
Sunesis Pharmaceuticals' Vosaroxin will be leading the charge, hopefully gaining regulatory traction both in the U.S. and the European Union. Read Article